Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models

Puerto Rico Health Sciences Journal

Volumn 29, Issue 1, 2010, Pages 4-17

  Otero Cruz, José David ^a   Báez Pagán, Carlos Alberto ^a   Dorna Pérez, Luisamari ^a   Grajales Reyes, Gary Emanuel ^a   Ramírez Ordoñez, Rosaura Teresa ^a   Luciano, Carlos A ^b   Gómez, Christopher Manuel ^c   Lasalde Dominicci, José Antonio ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acetylcholine receptor; Congenital myasthenic syndromes; Slow channel congenital myasthenic syndromes

Indexed keywords

ANIMAL; CONGENITAL MYASTHENIC SYNDROME; DISEASE MODEL; ELECTROMYOGRAPHY; GENE EXPRESSION; GENETICS; MOUSE; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTROMYOGRAPHY; GENE EXPRESSION; MICE; MYASTHENIC SYNDROMES, CONGENITAL;

EID: 77349088955     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: recent advances. Arch Neurol 1999;56:163-167.
2. Hantai D, Richard P, Koenig J, Eymard B. Congenital myasthenic syndromes. Curr Opin Neurol 2004;17:539-551.
3. Harper CM. Congenital myasthenic syndromes. Semin Neurol 2004; 24:111-123.
4. Engel AG. Congenital myasthenic syndromes. Neurol Clin 1994;12: 401-437.
5. Engel AG, Lambert EH, Mulder DM, et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982;11:553-569.
6. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102-114.
7. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000;40:431-458.
8. Le Novere N, Corringer PJ, Changeux JP. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 2002;53:447-456.
9. Unwin N. Nicotinic acetylcholine receptor at 9 A resolution. J Mol Biol 1993;229:1101-1124.
10. Devillers-Thiery A, Galzi JL, Eisele JL, Bertrand S, Bertrand D, Changeux JP. Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels. J Membr Biol 1993;136:97-112.
11. Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995;373:37-43.
12. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003;423:949-955.
13. Blanton MP, Cohen JB. Mapping the lipid-exposed regions in the Torpedo californica nicotinic acetylcholine receptor. Biochemistry 1992;31: 3738-3750.
14. Blanton MP, Cohen JB. Identifying the lipid-protein interface of the Torpedo nicotinic acetylcholine receptor: secondary structure implications. Biochemistry 1994;33:2859-2872.
15. Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve 2006;33:445-461.
16. Oosterhuis HJ, Newsom-Davis J, Wokke JH, et al. The slow-channel syndrome. Two new cases. Brain 1987;110:1061-1079.
17. Engel AG. Congenital myasthenic syndromes. Handb Clin Neurol 2008;91:285-331.
18. Ohno K, Hutchinson DO, Milone M, et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc Natl Acad Sci U S A 1995;92:758-762.
19. Milone M, Wang HL, Ohno K, et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci 1997;17:5651-5665.
20. Sine SM, Ohno K, Bouzat C, et al. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15:229-239.
21. Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217-1227.
22. Gómez CM, Maselli R, Gundeck JE, et al. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 1997;17:4170-4179.
23. Wintzen AR, Plomp JJ, Molenaar PC, et al. Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol 1998;44:657-664.
24. Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996;712:179-189.
25. Fukudome T, Ohno K, Brengman JM, Engel AG. AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome. Ann N Y Acad Sci 1998;841:199-202.
26. Fukudome T, Ohno K, Brengman JM, Engel AG. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 1998;9:1907-1911.
27. Harper CM, Engel AG. Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome. Ann N Y Acad Sci 1998; 841:203-206.
28. Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998;43:480-484.
29. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003;60:1710-1713.
30. Colomer J, Muller JS, Vernet A, et al. Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 2006;16:329-333.
31. Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007;4:252-257.
32. Neher E, Sakmann B. Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature 1976;260:799-802.
33. Colquhoun D, Hawkes AG. On the stochastic properties of single ion channels. Proc R Soc Lond B Biol Sci 1981;211:205-235.
34. Colquhoun D, Hawkes AG. On the stochastic properties of bursts of single ion channel openings and of clusters of bursts. Philos Trans R Soc Lond B Biol Sci 1982;300:1-59.
35. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
36. Gómez CM, Maselli R, Gammack J, et al. A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol 1996;39:712-723.
37. Croxen R, Newland C, Beeson D, et al. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1997;6:767-774.
38. Wang HL, Auerbach A, Bren N, Ohno K, Engel AG, Sine SM. Mutation in the M1 domain of the acetylcholine receptor alpha subunit decreases the rate of agonist dissociation. J Gen Physiol 1997;109:757-766.
39. Gómez CM, Maselli RA, Vohra BP, et al. Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 2002;51:102-112.
40. Croxen R, Hatton C, Shelley C, et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 2002;59:162-168.
41. Navedo MF, Lasalde-Dominicci JA, Baez-Pagán CA, et al. Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation. Mol Cell Neurosci 2006;32:82-90.
42. Shen XM, Deymeer F, Sine SM, Engel AG. Slow-channel mutation in acetylcholine receptor alphaM4 domain and its efficient knockdown. Ann Neurol 2006;60:128-136.
43. Zayas R, Lasalde-Dominicci J, Gomez CM. Macroscopic properties of spontaneous mutations in slow-channel syndrome: correlation by domain and disease severity. Synapse 2006;60:441-449.
44. Nirthanan S, Gwee MC. Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on. J Pharmacol Sci 2004;94:1-17.
45. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
46. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107:222-239.
47. Colquhoun D, Ogden DC. Activation of ion channels in the frog end-plate by high concentrations of acetylcholine. J Physiol 1988;395:131-159.
48. Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum Mol Genet 2003;12:2637-2644.
49. Elbashir SM, Martínez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 2001;20:6877-6888.
50. Gómez CM, Bhattacharyya BB, Charnet P, et al. A transgenic mouse model of the slow-channel syndrome. Muscle Nerve 1996;19:79-87.
51. Gómez CM, Maselli RA, Groshong J, et al. Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci 2002;22:6447-6457.
52. Vohra BP, Groshong JS, Zayas R, Wollmann RL, Gómez CM. Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis 2006;23:462-470.
53. Zayas R, Groshong JS, Gómez CM. Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome. Cell Calcium 2007;41: 343-352.
54. Groshong JS, Spencer MJ, Bhattacharyya BJ, et al. Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. J Clin Invest 2007;117:2903-2912.
55. Gómez CM, Gammack JT. A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome. Neurology 1995;45:982-985.
56. Bhattacharyya BJ, Day JW, Gundeck JE, Leonard S, Wollmann RL, Gómez CM. Desensitization of mutant acetylcholine receptors in transgenic mice reduces the amplitude of neuromuscular synaptic currents. Synapse 1997;27:367-377.
57. Namba T, Nakamura T, Grob D. Staining for nerve fiber and cholinesterase activity in fresh frozen sections. Am J Clin Pathol 1967;47:74-77.
58. Kashiwa HK. Calcium phosphate in osteogenic cells. A critique of the glyoxal bis(2-hydroxyanil) and the dilute silver acetate methods. Clin Orthop Relat Res 1970;70:200-211.
59. Rungby J, Kassem M, Eriksen EF, Danscher G. The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background. Histochem J 1993;25:446-451.
60. Noda M, Furutani Y, Takahashi H, et al. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor. Nature 1983;305:818-823.
61. Schoepfer R, Luther M, Lindstrom J. The human medulloblastoma cell line TE671 expresses a muscle-like acetylcholine receptor. Cloning of the alpha-subunit cDNA. FEBS Lett 1988;226:235-240.
62. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. Embo J 1990;9:2101-2106.
63. Keiger CJ, Prevette D, Conroy WG, Oppenheim RW. Developmental expression of nicotinic receptors in the chick and human spinal cord. J Comp Neurol 2003;455:86-99.
64. Beeson D, Brydson M, Newsom-Davis J. Nucleotide sequence of human muscle acetylcholine receptor beta-subunit. Nucleic Acids Res 1989;17:4391.
65. Heidmann O, Buonanno A, Geoffroy B, et al. Chromosomal localization of muscle nicotinic acetylcholine receptor genes in the mouse. Science 1986;234:866-868.
66. Lobos EA, Rudnick CH, Watson MS, Isenberg KE. Linkage disequilibrium study of RFLPs detected at the human muscle nicotinic acetylcholine receptor subunit genes. Am J Hum Genet 1989;44:522-533.
67. Pasteris NG, Trask BJ, Sheldon S, Gorski JL. Discordant phenotype of two overlapping deletions involving the PAX3 gene in chromosome 2q35. Hum Mol Genet 1993;2:953-959.
68. Beeson D, Brydson M, Betty M, et al. Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and epsilon subunits. Eur J Biochem 1993;215:229-238.
69. Vohra BP, Groshong JS, Maselli RA, Verity MA, Wollmann RL, Gómez CM. Focal caspase activation underlies the endplate myopathy in slow-channel syndrome. Ann Neurol 2004;55:347-352.